Citations

Showing 10 of 108119 citations.

Implications of uninterrupted preoperative transdermal buprenorphine use on postoperative pain management
Martin, Yvette N. , Pearson, Amy C S, Tranchida, John R, Schulte, Phillip J. , Pearson, Amy C. S. , Pearson, Amy C S , Pearson, Amy C S, Weingarten, Toby N. , Šprung, Juraj

Mayo Clinic

Regional Anesthesia & Pain Medicine | January 12, 2019 | Volume: 44 | Issue: 3 | Pages: 342-347

10.1136/rapm-2018-100018 | PMID 30635504 Get It

Background and objectives Buprenorphine is a partial µ-receptor agonist resistant to displacement from receptors by conventional opioids, which can block the effect of conventional opioids and may interfere with postoperative pain management. We aimed to quantify perioperative opioid use in patients receiving transdermal buprenorphine (TdBUP). Methods We identified patients receiving TdBUP who underwent surgery between 2004 and 2016. To compare opioid requirements (intravenous morphine equivalents (IV-MEq)), we constructed a matched study, matching each TdBUP patient with two opioid-naive patients by sex, age, and type of anesthesia and procedure. Results Nineteen unique patients underwent 22 procedures while receiving TdBUP. Total (IQR) amounts of IV-MEq (intraoperative, recovery room, and 24 hours after recovery-room discharge) were 98 (63, 145) and 46 (30, 65) mg IV-MEq for TdBUP and opioid-naive patients, respectively (p<0.001). Postoperative IV-MEq requirements were 54 (38, 90) and 15 (3, 35) mg for TdBUP and opioid-naive patients, respectively (p<0.001). Among TdBUP patients, higher preoperative doses of TdBUP were associated with greater postoperative opioid requirements (p=0.02). Specifically, patients with a 20 µg/hour TdBUP patch required 133.8 mg IV-MEq more postoperatively than patients with a 5 µg/hour patch (p=0.002). Following discharge from the recovery room, 17 (77%) TdBUP patients and 15 (34%) opioid-naive patients reported severe pain (OR 6.6 (95% CI 2.0 to 21.3); p<0.001; adjusting for baseline pain score, 5.0 (95% CI, 1.4 to 17.8); p=0.01). Conclusions Analgesic management for patients receiving TdBUP therapy must account for increased opioid needs, and greater preoperative doses of TdBUP were associated with greater postoperative opioid requirements.
The apnea test in brain death determination using oxygen diffusion method remains safe
Daneshmand, Ali , Rabinstein, Alejandro A. , Wijdicks, Eelco F. M.

Mayo Clinic

Neurology | January 12, 2019 | Volume: 92 | Issue: 8 | Pages: 386-387

10.1212/wnl.0000000000006963 | PMID 30635490 Get It

Transsylvian, Carotid-Oculomotor Triangle Approach for Resection of a Rapidly Enlarging Midbrain-Pontine Cavernous Malformation: 3-Dimensional Operative Video
Sorenson, Thomas J. , Castilla, Leonardo Rangel, Hughes, Joshua D, Rangel Castilla, Leonardo, Hughes, Joshua , Lanzino, Giuseppe

Mayo Clinic

Operative Neurosurgery | January 11, 2019 | Volume: 17 | Issue: 3 | Pages: E112-E112

10.1093/ons/opy390 | PMID 30649448 Get It

Abstract Cavernous malformations (CM) of the anterior midbrain are best reached through an orbitozygomatic (OZ) approach with removal of the orbital rim and wide Sylvian fissure dissection. Our surgical video demonstrates this approach to resect a ruptured CM in a 36-yr-old woman who presented with headaches, left face and left arm paresthesias/weakness, and right-sided partial oculomotor nerve (CN III) palsy. Initial magnetic resonance imaging (MRI) showed a midbrain CM, and the patient was managed conservatively. However, 1 wk later, she presented again with worsened left arm and leg weakness and complete CN III palsy. Seven Tesla MRI demonstrated a larger hematoma, and the CM with new mass effect and upper pons extension. The patient underwent a right modified OZ craniotomy and Sylvian fissure split under guidance of intraoperative neuronavigation and with neuromonitoring. The carotid-oculomotor triangle and the Liliequist membrane were dissected to access the midbrain, and CN III was identified and followed posteriorly to the midbrain. Confirmed with neuronavigation, a longitudinal incision of the midbrain was performed, and the CM was encountered. The hematoma and CM were debulked and removed in a piece-meal fashion, leaving hemosiderin-stained brain intact to prevent unnecessary additional damage to the midbrain. Postoperative MRI confirmed gross-total resection, and the patient's weakness recovered substantially. In this video, we demonstrate that the brainstem is no longer forbidden surgical territory, and show how the use of neuronavigation for surgical planning, positioning, and approach, in addition to the understanding of safe entry zones and meticulous microsurgical technique have made safe and effective surgery on the brainstem possible.
Timeline and location of recurrence following successful ablation in Barrett’s oesophagus: an international multicentre study
Sami, Sarmed S. , Ravindran, Adharsh, Snyder, Diana L. , Santiago, José , Ortiz‐Fernández‐Sordo, Jacobo , Tan, Wei Keith , Dierkhising, Ross , Johnson, Michele L., Lansing, Ramona, Ragunath, Krish , Pietro, Massimiliano di , Wolfsen, Herbert C. , Ramirez, Francisco C. , Fleischer, David E., Wang, Kenneth K, Leggett, Cadman L. , Katzka, David A. , Iyer, Prasad G. , Kahn, Allon , Snyder, Diana, Dierkhising, Ross A, Crook, Julia E. , Wolfsen, Herbert, Ramirez, Francisco, Fleischer, David, Katzka, D A , Iyer, P G , Leggett, Cadman L , Santiago, Jose, Heckman, Michael G.

Mayo Clinic

Gut | January 11, 2019 | Volume: 68 | Issue: 8 | Pages: 1379-1385

10.1136/gutjnl-2018-317513 | PMID 30635408 Get It

Objective Surveillance interval protocols after complete remission of intestinal metaplasia (CRIM) post radiofrequency ablation (RFA) in Barrett’s oesophagus (BE) are currently empiric and not based on substantial evidence. We aimed to assess the timeline, location and patterns of recurrence following CRIM to inform these guidelines. Design Data on patients undergoing RFA for BE were obtained from prospectively maintained databases of five (three USA and two UK) tertiary referral centres. RFA was performed until CRIM was confirmed on two consecutive endoscopies. Results 594 patients achieved CRIM as of 1 May 2017. 151 subjects developed recurrent BE over a median (IQR) follow-up of 2.8 (1.4–4.4) years. There was 19% cumulative recurrence risk of any BE within 2 years and an additional 49% risk over the next 8.6 years. There was no evidence of a clinically meaningful change in the recurrence hazard rate of any BE, dysplastic BE or high-grade dysplasia/cancer over the duration of follow-up, with an estimated 2% (95% CI −7% to 12%) change in recurrence rate of any BE in a doubling of follow-up time. 74% of BE recurrences developed at the gastro-oesophageal junction (GOJ) (24.1% were dysplastic) and 26% in the tubular oesophagus. The yield of random biopsies from the tubular oesophagus, in the absence of visible lesions, was 1% (BE) and 0.2% (dysplasia). Conclusions BE recurrence risk following CRIM remained constant over time, suggesting that lengthening of follow-up intervals, at least in the first 5 years after CRIM, may not be advisable. Sampling the GOJ is critical to detecting recurrence. The requirement for random biopsies of the neosquamous epithelium in the absence of visible lesions may need to be re-evaluated.
Endoscopic scar assessment after colorectal endoscopic mucosal resection scars: when is biopsy necessary (EMR Scar Assessment Project for Endoscope (ESCAPE) trial)
Kandel, Pujan , Brand, Eelco C. , Pelt, Joe , Ball, Colleen T. , Chen, Wei‐Chung , Bouras, Ernest P., Gómez, Victoria , Woodward, Timothy A., Wallace, Michael B. , Raimondo, Massimo , Wallace, Michael B

Mayo Clinic

Gut | January 11, 2019 | Volume: 68 | Issue: 9 | Pages: 1633-1641

10.1136/gutjnl-2018-316574 | PMID 30635409 Get It

Objective It is unclear whether endoscopic assessment of scars after colorectal endoscopic mucosal resection (EMR) has to include biopsies, even if endoscopy is negative. Vice versa, endoscopic diagnosis of recurrent adenoma may not require biopsy before endoscopic reinterventions. We prospectively analysed various endoscopic modalities in the diagnosis of recurrence following EMR. Design We conducted a prospective study of patients undergoing colonoscopy after EMR of large (≥20 mm) colorectal neoplasia. Endoscopists predicted recurrence and confidence level with four imaging modes: high-definition white light (WL) and narrow-band imaging (NBI) with and without near focus (NF). Separately, 26 experienced endoscopists assessed offline images. Results Two hundred and thirty patients with 255 EMR scars were included. The prevalence of recurrent adenoma was 24%. Diagnostic values were high for all modes (negative predictive value (NPV) ≥97%, positive predictive value (PPV) ≥81%, sensitivity ≥90%, specificity ≥93% and accuracy ≥93%). In high-confidence cases, NBI with NF had NPV of 100% (95% CI 98% to 100%) and sensitivity of 100% (95% CI 93% to 100%). Use of clips at initial EMR increased diagnostic inaccuracy (adjusted OR=1.68(95% CI 1.01 to 2.75)). In offline assessment, specificity was high for all imaging modes (mean: ≥93% (range: 55%–100%)), while sensitivity was significantly higher for NBI-NF (82%(72%–93%)%)) compared with WL (69%(38%–86%); p<0.001), WL-NF (68%(55%–83%); p<0.001) and NBI (71%(59%–90%); p<0.001). Conclusion Our study demonstrates very high sensitivity and accuracy for all four imaging modalities, especially NBI with NF, for diagnosis of recurrent neoplasia after EMR. Our data strongly suggest that in cases of high confidence negative optical diagnosis based on NBI-NF, no biopsy is needed to confirm absence of recurrence during colorectal EMR follow-up. A high confidence positive optical diagnosis can lead to immediate resection of any suspicious area. In all cases of low confidence, biopsy is still required. Trial registration number NCT02668198 .
Immunophenotype switching in cutaneous T-cell lymphoma: nature or nurture?
Ansell, Stephen M.

Mayo Clinic

Leukemia & Lymphoma | January 11, 2019 | Volume: 60 | Issue: 5 | Pages: 1114-1115

10.1080/10428194.2018.1543887 | PMID 30632848 Get It

Response to Weisschuh’s “Comment: a novel missense mutation in BEST1 associated with an autosomal-dominant vitreoretinochoroidopathy (ADVIRC) phenotype”
Mano, Fukutaro , Pfannkoch, Cynthia, Olsen, Timothy W. , Marmorstein, Alan D. , Pulido, José S. , LoBue, Stephen A , Marmorstein, Alan D

Mayo Clinic

Ophthalmic Genetics | January 11, 2019 | Volume: 40 | Issue: 1 | Pages: 88-89

10.1080/13816810.2018.1558264 | PMID 30632873 Get It

Abdominal Pain, Fevers, and Intestinal Lymphangiectasia
Yetmar, Zachary A. , Cevallos, Edison Cano , Mahmood, Maryam , Cano Cevallos, Edison, Yetmar, Zachary A , Cano Cevallos, Edison Jose , Mahmood, Maryam

Mayo Clinic

Clinical Infectious Diseases | January 11, 2019 | Volume: 69 | Issue: 11 | Pages: 2035-2036

10.1093/cid/ciz041 | PMID 31724060 Get It

A Witness to Being
Liu, Joy

Mayo Clinic

Journal of Palliative Medicine | January 11, 2019 | Volume: 22 | Issue: 1 | Pages: 103-105

10.1089/jpm.2018.0277 | PMID 30633699 Get It